Stay updated on Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision indicator updated from v3.3.3 to v3.3.4; this change does not affect study content or user experience. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedExpanded Locations section with numerous new sites across the US, Argentina, Australia, and many other countries.SummaryDifference3%

- Check61 days agoChange DetectedAdded clarifying sentences about how publications are provided and automatically filled from PubMed, and updated the Revision to v3.3.2. The deletions remove older wording describing the PubMed-derived list and the previous revision number.SummaryDifference0.1%

- Check68 days agoChange DetectedRemoved the government funding/operating status notice from the page, which previously informed users about potential delays and site status. This change does not affect the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check89 days agoChange DetectedThe screenshots show no substantive updates to the study record beyond minor formatting changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check111 days agoChange DetectedAdds a government-status notice and a new software version (v3.2.0); removes the old version tag (v3.1.0).SummaryDifference2%

Stay in the know with updates to Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.